The risk of diabetes mellitus in children born small for gestational age and treated with recombinant growth hormone.
Children born small for gestational age (SGA) are known to be at risk for both short stature and type 2 diabetes mellitus in later life. To evaluate the influence of recombinant growth hormone (rhGH) therapy on insulin sensitivity, 24 children born SGA were treated with GH at traditional doses, from 0.23 mg/kg/week (group A) to 0.46 mg/kg/week (group B). We evaluated glycosylated haemoglobin, basal glucose and insulin levels before and 1 and 2 years after GH therapy. The homeostasis model assessment (HOMA) index was used to evaluate insulin sensitivity. After 2 years of GH therapy, glycosylated haemoglobin and basal glucose did not change significantly. Insulin sensitivity fell, but still remained within the normal range. In conclusion, 2-year GH therapy had beneficial effects in SGA children without changes in glucose homeostasis. Moreover, the insulin sensitivity reduction did not correlate to the GH dose used.
Bozzola
E
E
Department of Paediatrics, University of Pavia, Italy. m.bozzola@smatteo.pv.it
Lauriola
S
S
Messina
M F
MF
Bona
G
G
Wasniewska
M
M
Bozzola
M
M
Tatò
L
L
D000367:Age Factors; D001786:Blood Glucose / Q000032:analysis / Q000378:metabolism*; D002648:Child; D002675:Child, Preschool; D003924:Diabetes Mellitus, Type 2 / Q000209:etiology* / Q000517:prevention & control; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006706:Homeostasis; D019382:Human Growth Hormone / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000097:blood; D007231:Infant, Newborn; D007236:Infant, Small for Gestational Age; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D008297:Male; D012307:Risk Factors
D001786:Blood Glucose; D006442:Glycated Hemoglobin; D019382:Human Growth Hormone; D007004:Hypoglycemic Agents; D007328:Insulin